3rd Quarter - Report
BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA MALAKOFF | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.